Skip to content
PeptideFactSheets
Preclinical researchMostly animal or lab research

Plain-English fact sheet

MOTS-c

Also known as MOTS-c peptide, mitochondrial ORF of 12S rRNA type-c

Mitochondrial healthMetabolic healthMuscle and performanceHealthy aging research

MOTS-c is made from a small mitochondrial gene and has promising animal and cell research, while direct human treatment evidence and safety data are essentially absent.

Quick answer

MOTS-c is an experimental mitochondrial-derived peptide studied for metabolism, exercise adaptation, and aging biology. It is not FDA approved, and FDA reports no identified human exposure data for drug products containing MOTS-c.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and produced as part of cellular stress and metabolic signaling.

Studies measuring natural MOTS-c levels in people are not treatment trials, and a synthetic analog such as CB4211 is not interchangeable with native MOTS-c.

Why are people interested in it?

Animal studies report effects on insulin sensitivity, metabolic stress, physical capacity, and age-related decline.

Those findings have fueled 'exercise mimetic' and longevity claims that go far beyond direct human intervention evidence.

Current regulatory status

Preclinical research

No MOTS-c drug product is FDA approved. FDA's current compounding safety summary states that it has not identified human exposure data for drug products containing MOTS-c.

What is it approved for?

No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.

FDA approval path

Preclinical research

Native MOTS-c remains preclinical as a treatment

Most treatment claims rely on animal or laboratory work. A related CB4211 analog reached Phase 1, but that analog is not interchangeable with native MOTS-c.

Step 2 of 7

  1. DiscoveryBasic research
  2. PreclinicalLab and animal work
  3. Phase 1Initial human testing
  4. Phase 2Condition-focused trials
  5. Phase 3Confirmatory trials
  6. FDA reviewApplication review
  7. ApprovedLabel-specific use

Timeline source basis

FDA: safety risks for selected compounded bulk substancesMOTS-c metabolism and insulin-sensitivity studyClinicalTrials.gov: CB4211 Phase 1 study

What is it being studied for?

Insulin sensitivity and metabolic regulation in animal models
Exercise adaptation and physical capacity
Age-related metabolic decline
Muscle stress and mitochondrial signaling

Investigational areas

  • Metabolic disease and fatty-liver research
  • Exercise and muscle-function biology
  • Healthy-aging mechanisms

Evidence snapshot

Mostly animal or lab research

Most treatment claims come from cells and animals. Human studies largely measure naturally circulating MOTS-c or response to exercise rather than test MOTS-c as a therapy.

Potential benefits being researched

  • Animal studies report improved insulin sensitivity and physical capacity under selected experimental conditions.
  • Human observational work shows associations with exercise and muscle measures, but association does not prove that administering MOTS-c produces a benefit.

Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.

Known or possible risks

  • FDA identifies potential immune reactions and complexities involving peptide impurities and active-ingredient characterization.
  • There is no adequate human treatment dataset from which to estimate common, uncommon, or long-term harms.
  • Unapproved products add identity, purity, sterility, strength, and labeling risks.

What we still do not know

  • Whether administered MOTS-c produces any meaningful human metabolic or performance benefit
  • Short- and long-term human safety
  • How synthetic products compare with the naturally produced peptide
  • Whether animal longevity or exercise findings translate to people

Related research updates

Elamipretide confirmatory trial appears after accelerated approval

Plain-English takeaway

MOTS-c is compelling mitochondrial biology, not a proven exercise or longevity treatment. The missing step is direct, controlled human evidence with a characterized product.

Research and reference links

Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.

  1. 1
    fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

  2. 2
    pubmedMOTS-c metabolism and insulin-sensitivity study

    Preclinical study in animal models; it does not establish a human treatment effect.

  3. 3
    pubmedHuman exercise study of mitochondrial-derived peptides

    Study of naturally circulating peptide levels after exercise, not administration as a therapy.

  4. 4
    clinical trialsClinicalTrials.gov: CB4211 Phase 1 study

    Completed early trial of a MOTS-c analog; the registry does not show public results and the analog is not native MOTS-c.